Grifols (NASDAQ:GRFS) Shares Cross Below 200 Day Moving Average – Here’s Why

Shares of Grifols, S.A. (NASDAQ:GRFS) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $8.37 and traded as low as $7.13. Grifols shares last traded at $7.21, with a volume of 976,362 shares changing hands.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on GRFS. Weiss Ratings lowered shares of Grifols from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Wall Street Zen downgraded Grifols from a “buy” rating to a “hold” rating in a report on Monday, May 18th. Finally, Zacks Research cut Grifols from a “hold” rating to a “strong sell” rating in a report on Friday, May 8th. Two research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Grifols currently has an average rating of “Reduce” and an average target price of $10.00.

Grifols Price Performance

The business’s 50-day simple moving average is $7.66 and its two-hundred day simple moving average is $8.37. The stock has a market cap of $4.91 billion, a price-to-earnings ratio of 37.95, a price-to-earnings-growth ratio of 0.28 and a beta of 0.67. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.47 and a quick ratio of 0.85.

Grifols Dividend Announcement

The company also recently announced a special dividend, which will be paid on Thursday, July 9th. Shareholders of record on Thursday, July 2nd will be issued a $0.0945 dividend. The ex-dividend date of this dividend is Thursday, July 2nd. Grifols’s dividend payout ratio is presently 110.53%.

Institutional Trading of Grifols

Several hedge funds and other institutional investors have recently made changes to their positions in GRFS. Versant Capital Management Inc raised its holdings in Grifols by 36.0% in the 2nd quarter. Versant Capital Management Inc now owns 6,958 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 1,842 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in Grifols by 71.6% in the 1st quarter. EverSource Wealth Advisors LLC now owns 14,685 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 6,127 shares during the period. Royal Bank of Canada raised its stake in shares of Grifols by 15.4% during the first quarter. Royal Bank of Canada now owns 785,703 shares of the biotechnology company’s stock valued at $6,301,000 after acquiring an additional 104,850 shares during the last quarter. Quantinno Capital Management LP lifted its holdings in shares of Grifols by 42.0% during the first quarter. Quantinno Capital Management LP now owns 352,798 shares of the biotechnology company’s stock worth $2,829,000 after purchasing an additional 104,418 shares during the period. Finally, Flat Footed LLC lifted its holdings in shares of Grifols by 26.5% during the first quarter. Flat Footed LLC now owns 1,372,394 shares of the biotechnology company’s stock worth $11,007,000 after purchasing an additional 287,867 shares during the period.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.